PharmaCyte Biotech shared an update from their meeting with leading clinical oncologists interested in PharmaCyte’s planned clinical trial in locally advanced pancreas cancer.
PharmaCyte Biotech (OTCQB:PMCB) shared an update from their meeting with leading clinical oncologists interested in PharmaCyte’s planned clinical trial in locally advanced pancreas cancer.
As quoted in the press release:
The meeting was by invitation only during this year’s 53rd annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
During the meeting, PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, updated the attendees on the company’s efforts to advance its pancreas cancer therapy into a pivotal clinical trial. Dr. Matthias Löhr, the Chairman of PharmaCyte’s Medical and Scientific Advisory Board and the Principal Investigator for the two previous clinical trials using PharmaCyte’s pancreas cancer therapy, along with Dr. Ronald L. Korn, Founder and Chief Medical Officer of Imaging Endpoints, and Susan Tessmann, the Director of Clinical Operations at Translational Drug Development (TD2), made presentations on the progress that has been made and the path forward to the clinic. This was the first update since PharmaCyte’s pancreas cancer therapy was first introduced to a group of leading oncologists at last year’s annual meeting of ASCO. TD2 and Imaging Endpoints are the two major CROs who will be conducting the trial for PharmaCyte.